A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy male or female 18 to 65 years of age at Screening, inclusive
Body mass index (BMI) 18.5 to 32 kg/m\^2, inclusive
Body weight 50 to 100 kg, inclusive
Females must be of non-childbearing potential
Males of reproductive potential must agree to remain abstinent or must be using highly effective contraception and must avoid sperm donation, from Screening until at least 8 weeks after the last study drug administration or until study completion, whichever is later
You may not be if
Significant medical history, psychiatric disorder, or acute infection at Screening (as determined by Investigator)
History of alcoholism or drug addiction within 6 months prior to CRU Check-in
Use of tobacco or nicotine-containing products from 6 months prior to CRU Check-in and during the study
Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred wtihin 30 days or 5 half-lives, whichever is longer, prior to CRU Check-in
Clareo Health | A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose
